ADA

As Diabetes Numbers Rise, Costs Mount
As Diabetes Numbers Rise, Costs MountThe pharmacist's role in diabetes care will only continue to grow.
Five advancements in diabetes treatment to watch
Five advancements in diabetes treatment to watchThe healthcare industry continues to focus efforts on treatments that work better, and ideally are less expensive and less invasive for patients.
Community pharmacists take on prediabetesIn 2012, approximately 37% of the adults in America had prediabetes, and almost 90% of them didn't realize it. The importance of intervention/education by community pharmacists cannot be overestimated.
T2DM and CVD: Monitoring by pharmacists empowers patientsType 2 diabetes is associated with a two- to four-fold increase in the risk of CVD. Pharmacists can monitor and manage the risk factors.
I have been sued under the ADAThe Americans with Disabilities Act of 1990 (ADA) provides a general legal framework for access of individuals with disabilities to public places and also for accommodating employees with disabilities in the workplace. Although the ADA contains very specific guidance for physical accommodations, such as wheelchair access, it provides little guidance relevant to workers with conditions such as diabetes.
Pharmacist with needle phobia wins millions from Rite AidShould a pharmacist afraid of needles have to administer immunizations as part of his or her job? Or should pharmacies be required to make reasonable accommodations for such an employee?
ADA: Study says non-insulin dulaglutide demonstrates effective blood glucose control in diabetes patientsAmerican Diabetes Association Scientific Sessions in San Francisco, showed that investigational, non-insulin, once-weekly dulaglutide 1.5 mg provided significant blood glucose control for patients with type 2 diabetes.
ADA: Studies point to safety, efficacy profile for new insulin glargine productLY2963016 insulin glargine has a similar safety and efficacy profile to currently marketed insulin glargine, according to data recently presented the American Diabetes Association (ADA) Scientific Sessions in San Francisco.
ADA: Empagliflozin versus placebo controlled patients with type 2 diabetes on multiple daily insulin injectionsIn a 52-week study of obese adults with type 2 diabetes on high insulin doses with or without metformin, adding empagliflozin to multiple daily insulin injections significantly reduced blood glucose and body weight with lower insulin doses compared with placebo, according to data recently presented at the American Diabetes Association (ADA) Scientific Sessions in San Francisco.
ADA: Empagliflozin added to metformin showed greater reductions in blood glucose, body weight versus glimepirideIn a 2-year study, empagliflozin as add-on to metformin demonstrated significantly greater decreases in hemoglobin A1c (a measure of average blood glucose over the past 2 to 3 months), body weight and blood pressure compared with glimepiride as add-on to metformin in adults with type 2 diabetes.